Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
about
Pharmacotherapy of systemic sclerosisRecent developments in myofibroblast biology: paradigms for connective tissue remodelingAssessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?Increased dermal collagen bundle alignment in systemic sclerosis is associated with a cell migration signature and role of Arhgdib in directed fibroblast migration on aligned ECMsB cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosisThe skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.An automated image processing method to quantify collagen fibre organization within cutaneous scar tissue.Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosisSustained β-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes.A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related FibrosisToll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts.Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological studyApplication of biomarkers to clinical trials in systemic sclerosis.Clinicopathological characteristics of immunoglobulin G4-related sialadenitisOsteopontin in systemic sclerosis and its role in dermal fibrosisFresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patientsB cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosisValidity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trialFibroblast abnormalities in the pathogenesis of systemic sclerosis.Quantitating skin fibrosis: innovative strategies and their clinical implications.Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease.Transforming growth factor β--at the centre of systemic sclerosis.Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis.A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.Subclinical dermal involvement is detectable by high frequency ultrasound even in patients with limited cutaneous systemic sclerosis.An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement.Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis.The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis.Pathological changes in basement membranes and dermal connective tissue of skin from patients with hereditary cystatin C amyloid angiopathy.Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.Histopathological changes in morphea and their clinical correlates: Results from the Morphea in Adults and Children Cohort V.
P2860
Q24629481-FE624586-D138-4435-931C-D289A5727379Q26863751-A4FE9EA3-C2D5-4199-8CA7-92CD322365A5Q33536943-1706B657-F357-42A0-B40D-348DFB4BF109Q33853799-1E1D34BE-75A9-41B8-8B4E-6BF309AEE362Q33923359-8DAE1D80-4B2B-439B-BBD5-9E98493EDA21Q33923580-0068B047-8B45-4678-B341-8608064E3B65Q34310749-BFA9CAD4-3F86-49AB-8BCE-77B2AEFBE886Q34899566-2E1F969F-5BA3-4D2D-A57D-3D33DC3437A2Q35158836-7131B15D-61B8-4AE2-9F41-89CB1C11E199Q35171136-7782DEAE-CEC8-443A-92D1-79AE843245BCQ35587696-FF03C51D-B7AE-4F44-B01B-2EFB180C25CFQ35620268-8F7EBA7E-7054-414F-A207-30DD1B9C7FFCQ35620376-AB330C07-8EC6-48F5-86E0-40CF7298DCD8Q35681874-80CB8DF8-B1DA-4F6A-8BF7-6AC1819323CBQ35869679-BE8348B7-44C9-4097-BB53-3C6ECF45092CQ36002290-5DD6B326-7BB1-4CB4-BBCC-8349FDB424F5Q36040200-1B2FA127-912E-40C5-8538-7CB0342AF2E6Q37088694-C9221CB9-AB9A-4F82-9E28-FAE3F3040BAFQ37460808-071D78EA-C9EC-4C75-8E89-3A319BE16BEFQ37905795-DA5DF113-A63F-49ED-9BD8-BDD87B58F5C9Q38180018-2055B591-4C68-491D-8BC6-6C1B075B1B8BQ38204104-467A0B99-60DE-4C9B-B6F9-3EAE7239C355Q38241227-BC4251A0-018D-4D6F-A68B-687E68E10AF9Q38771824-49C563AA-C390-4B27-A678-1A21C3BD83C8Q41630154-912F2A9C-D9C7-44F2-84E0-0C791BAB8AB9Q41789272-B6B39B2C-F8F1-47E1-8A4D-8BD59BA988E8Q41900693-3D3C0804-59AA-4FE7-BAF7-05AEB6AD4F2CQ42159140-E2DBF280-4848-43EC-9A85-2F40F168079CQ42314961-76FC7664-1A49-4E01-9894-0183C3134A9AQ45920167-3EF495E3-AE25-4E37-9B43-498230E09E6CQ46474228-FC8792D1-D9D8-4178-BCD5-E08C5A8F5944Q47400242-704579BE-5FCE-4A3D-A179-25DE96711E3AQ47583542-A411FCC6-75F1-4411-8D48-B7158C370FE0Q48365948-DAC5D5BD-3C0F-4778-ABC2-7E7572BC2BA6Q53512767-C7610CA1-ED24-4085-8A19-6B8D6876AE11Q54912167-D2D471B7-5D99-47C5-B200-CF38038A261E
P2860
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
@ast
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
@en
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
@nl
type
label
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
@ast
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
@en
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
@nl
prefLabel
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
@ast
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
@en
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
@nl
P356
P1476
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.
@en
P2093
Peter A Merkel
P304
P356
10.1002/ART.22186
P577
2006-11-01T00:00:00Z